Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Berg

Interventional Pain Medicine Louisville, KY Medical Doctor

NPI 1376506022 CMS profile 16374

1169 Eastern Pkwy Ste 2211, Louisville, KY 40217

Open in the dashboard

General payments

$3,206

185 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Berg of Louisville, KY is reported in the CMS Open Payments database as having received $3,206 across 185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $311 15
2024 General $504 17
2023 General $244 14
2022 General $453 21
2021 General $615 42
2020 General $596 44
2019 General $483 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Berg
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jeffrey Berg were reported at $311. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jeffrey Berg Interventional Pain Medicine median Middle half National median
2019 $483 $684 $216–$2,079 $163
2020 $596 $382 $122–$1,109 $114
2021 $615 $552 $167–$1,554 $132
2022 $453 $605 $187–$1,924 $149
2023 $244 $671 $195–$1,915 $160
2024 $504 $684 $206–$1,837 $164
2025 $311 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collegium Pharmaceutical, Inc. $738 40 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $507 27 payments
  3. AbbVie, Inc. $348 22 payments
  4. Boston Scientific Corporation $272 7 payments
  5. Pfizer Inc. $265 19 payments
  6. GRT US Holding, Inc. $230 13 payments
  7. Allergan Inc. $147 14 payments
  8. Biohaven Pharmaceuticals, Inc. $142 8 payments
  9. Scilex Pharmaceuticals Inc. $90 6 payments
  10. Biodelivery Sciences International, Inc. $74 5 payments
  11. Other $394 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,206 185 payments
Products named General payments · program years 2019–2025
  1. RELISTOR $440 24 payments
  2. XTAMPZA $413 24 payments
  3. BELBUCA $325 16 payments
  4. UBRELVY Neuroscience $287 16 payments
  5. Qutenza $230 13 payments
  6. NURTEC ODT $190 11 payments
  7. LYRICA $126 9 payments
  8. EMBEDA $97 7 payments
  9. LUCEMYRA $93 6 payments
  10. UBRELVY Neuroscience $86 10 payments
  11. Other $999 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

6,838

Median for Interventional Pain Management: 1,220

Drug cost

$245,559

Median for Interventional Pain Management: $39,344

Branded share of claims

75.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 3,994 $73,684
Belbuca Buprenorphine Hcl Brand 72 $60,051
Buprenorphine Generic 65 $25,000
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 927 $20,418
Nucynta Tapentadol Hcl Brand 11 $15,671
Oxycontin Oxycodone Hcl Brand 19 $15,508
Hysingla Er Hydrocodone Bitartrate Brand 12 $8,129
Xtampza Er Oxycodone Myristate Brand 11 $7,543
Gabapentin Generic 380 $4,189
Tramadol Hcl Generic 539 $3,748

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$241,765

Of which drugs: $11,733

Medicare patients

423

Average age 72

Services billed

33,409

249 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 30%
Depression 29%
COPD 28%
Chronic kidney disease 23%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 221 24,770 $7,002
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 261 4,644 $3,424
Injection, methocarbamol, up to 10 ml J2800 Office 24 27 $107
Injection, ketorolac tromethamine, per 15 mg J1885 Office 20 80 $44
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 18 460 $41
Injection, midazolam hydrochloride, per 1 mg J2250 Office 28 265 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $135
$135 11 —
BELBUCA
  • Collegium Pharmaceutical, Inc. $130
$130 72 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record